Owing to its central role in autophagy regulation, druggable nature, and apparent selectivity over other autophagy inhibitors, along with minimal effect on normal CD34 (+) cells, ULK1 represents a promising molecular target for FLT3-ITD AML treatment. The gene discussed is ULK1; the disease is acute myeloid leukemia.